Aclaris Therapeutics - 9 Asse im Ärmel!

Seite 1 von 6
neuester Beitrag: 09.10.20 21:19
eröffnet am: 03.05.19 12:25 von: moneywork4. Anzahl Beiträge: 144
neuester Beitrag: 09.10.20 21:19 von: Balu4u Leser gesamt: 16851
davon Heute: 11
bewertet mit 1 Stern

Seite: 1 | 2 | 3 | 4 | 5 | 6 | 6   

03.05.19 12:25
1

541 Postings, 546 Tage moneywork4meAclaris Therapeutics - 9 Asse im Ärmel!

Interessanter Biotech-Wert mit einer prallen Pipeline

https://www.aclaristx.com/pipeline/

https://www.aclaristx.com/

Kursziele bis 50 USD (Kurs aktuell: 6,06 USD)

April 26, 2019   Healthcare, Top Market News   0 Comments
Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)
By Carrie Williams

[Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)] In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRS ? Research Report), with a price target of $50. The company?s shares closed yesterday at $6.83, close to its 52-week low of $5.04.

Chen commented:

   ?We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of 50 USD.

https://www.analystratings.com/articles/...ris-therapeutics-inc-acrs/  
Seite: 1 | 2 | 3 | 4 | 5 | 6 | 6   
118 Postings ausgeblendet.

10.07.20 21:31

5817 Postings, 4208 Tage Kleine_prinzBald müsste es news darüber geben..

If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

 

17.07.20 11:21

5817 Postings, 4208 Tage Kleine_prinzInteressant..

New Drug for COVID-19 Treatment is Developed in St. Louis with Clinical Trial in Kansas

--------------------------------------------------

Aclaris is supporting an investigator-initiated trial of ATI-450 in 36 hospitalized patients with COVID-19, and will provide funding and the clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial located in Kansas City, Kansas.

The clinical trial is underway to treat patients with the novel coronavirus because COVID-19 can cause acute respiratory distress syndrome, ARDS.

“Literature that’s come out over the last four or five months suggests one of the causes of ARDS is a hyperactive immune response, so the immune system is triggered when you get the viral infection, but for some reason the immune system goes a little haywire and this results in an inflammatory state,” explained Monahan. “The data suggests that this inflammatory state, this hyperinflammation, is associated with an upregulation of certain proteins that come from both diseased tissue and immune cells, called cytokines. And these cytokines could be the culprit in driving this ARDS and the inflammation seen in the lung in COVID-19 patients.”

Monahan explained the reason it’s believed ATI-450 will work as a rheumatoid arthritis treatment is because the drug downregulates cytokines, inhibiting their production.

https://www.hecmedia.org/posts/...uis-with-clinical-trial-in-kansas-3

 

21.07.20 08:44

19767 Postings, 3858 Tage Balu4u2,45USD +0,24USD +10,86%

Neues Jahreshoch





 

22.07.20 17:49

19767 Postings, 3858 Tage Balu4uImmer wieder Ausbruchsversuche...

10.08.20 16:16

5817 Postings, 4208 Tage Kleine_prinzSchaut ganz gut aus viel Potenzial..

     First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis
      •     First Subject Dosed in Phase 2a Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
      •     Clinical Trial of ATI-1777, an Investigational “Soft” Topical JAK 1/3 Inhibitor, to Proceed in Patients with Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights

Aclaris Therapeutics, Inc.

GlobeNewswireAugust 7, 2020

--------------------------------------------------

R&D Highlights:
The global outbreak of COVID-19 continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its regulatory and research and development activities listed below.

  • ATI-450, an investigational oral small molecule MK2 inhibitor compound:
    • ATI-450-RA-201: An ongoing Phase 2a trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis.
      • This trial was initiated in March 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment. Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, Aclaris is actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, Aclaris now anticipates reporting data from this trial in the first half of 2021.
    • ATI-450-CAPS-201: Aclaris expects to initiate a Phase 2a clinical trial of ATI-450 in cryopyrin-associated periodic syndrome (CAPS), an IL1β-driven disease, in the second half of 2020.
    • IIT-2020-ATI-450-COVID-19: An ongoing investigator-initiated Phase 2a, randomized, double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of ATI-450, when used in addition to standard of care therapy, as a potential treatment for cytokine release syndrome in 36 hospitalized patients with COVID-19. Aclaris is providing funding and clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial. The primary endpoint in this trial is the proportion of subjects who are free from respiratory failure by day 14.
      • The first subject was dosed in August 2020.
  • ATI-1777, an investigational topical “soft” Janus Kinase (JAK) 1/3 inhibitor compound:
    • Aclaris submitted an Investigational New Drug (IND) Application for ATI-1777 for the treatment of moderate to severe atopic dermatitis (AD) in June 2020 and now plans to progress to the first-in-human trial of ATI-1777 in subjects with moderate to severe AD.
    • ATI-1777-AD-201: Aclaris expects to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020. The primary endpoint will assess efficacy at four weeks.
  • ATI-2138, an investigational oral ITK/TXK/JAK3 (ITJ) inhibitor compound:
    • Aclaris is developing ATI-2138 as a potential treatment for psoriasis and/or inflammatory bowel disease and expects to submit an IND for ATI-2138 in 2021.

Business Development Highlights:

  • Aclaris continues to pursue strategic alternatives, including seeking partners for:
    • A-101 45% Topical Solution: to obtain regulatory approval and commercialize A-101 45% Topical Solution, an investigational compound, as a potential treatment for common warts (verruca vulgaris);
    • ATI-501 & ATI-502: to further develop, obtain regulatory approval and commercialize ATI-501 (oral) and ATI-502 (topical), investigational JAK 1/3 inhibitor compounds, as potential treatments for alopecia; and
    • ESKATA: to commercialize ESKATA® (hydrogen peroxide) topical solution, 40% (w/w).

 https://finance.yahoo.com/news/aclaris-therapeutics-reports-second-quarter-110000807.html?guce_referrer=aHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9xdW90ZS9BQ1JTP3A9QUNSUyZndWNlX3JlZmVycmVyPWFIUjBjSE02THk5bWFXNWhibU5sTG5saGFHOXZMbU52YlM5eGRXOTBaUzlCUTFKVFAzQTlRVU5TVXcmZ3VjZV9yZWZlcnJlcl9zaWc9QVFBQUFJaGJkWldWel9DYnItOXpSNzlRVF9UdEdOQUo1blVxaHFCVFFOYVRTcWJwSW5XbTNqclRySDlkNWtVRUUwZHotamN6ancwQzZwTVpfM1BZR3dUemk2ckM0TW5hZjVKNWRYMTJSTEcza0N4ak9YRHdqQnotVXJ6SW9hSnYzX3VOMHMzNVFlYUlNTktpbzA5MHNILTA4eDljMnA2bTZub2tyems3WlMzZmF0UlUmX2d1Y19jb25zZW50X3NraXA9MTU5NzA2NzE5Ng&guce_referrer_sig=AQAAALheF0dImmwxQJqLNmUbnFSb88NiCQdOU9UmSq4gGnHtjfuWJpX5Wuf51vt7QMJXDg7KJYZ5tkHOiVy4Zam0KZMSasjsJM-eKsxlFxKp02-Gatfj74LTnZhoyUqFf4tg_dBicbFiwdHpqc-ZFohWshWfuNL2jprjNGK7luqBMNhp&_guc_consent_skip=1597068326

 

10.08.20 16:36

5817 Postings, 4208 Tage Kleine_prinzInterantes Video ATI-450 Trial ect..

New Drug for COVID-19 Treatment is Developed in St. Louis with Clinical Trial in Kansas

https://www.youtube.com/watch?v=9TDDvTYNRfM

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

https://clinicaltrials.gov/ct2/show/study/NCT04481685

 

11.08.20 19:01

19767 Postings, 3858 Tage Balu4uBrauchen mal nen nachhaltigen Anstieg!

14.08.20 17:39

5817 Postings, 4208 Tage Kleine_prinzLincoln Park Transaction..

This prospectus supplement relates to the issuance and sale of up to $15,000,000 of shares of our common stock that we may sell to Lincoln Park Capital Fund, LLC, or Lincoln Park, from time to time pursuant to the purchase agreement, dated August 13, 2020, or the Purchase Agreement, that we have entered into with Lincoln Park, and an additional 121,584 shares of our common stock being issued to Lincoln Park as commitment shares under the Purchase Agreement. See “Lincoln Park Transaction” for a description of the Purchase Agreement and additional information regarding Lincoln Park. Lincoln Park is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act.

https://investor.aclaristx.com/node/10391/html

 

15.08.20 19:16

5817 Postings, 4208 Tage Kleine_prinzBald müssten news kommen zu ATI-450 COVID-19

Aclaris Update 8/7/2020: First Patient Dosed In Phase 2a Trial Of ATI-450 In Hospitalized Patients With COVID-19

Aug. 8, 2020 2:35 AM ET|About: Aclaris Therapeutics, Inc. (ACRS), Includes: CAPR, CODX, EDSA, IMRN, INO, NVAX, SRNE, VXRT

Summary

On August 7, 2020, Aclaris Therapeutics reported that the first patient had been dosed with ATI-450 in the company's investigator-initiated Phase 2a COVID-19 clinical trials.

The trial is a Phase 2a, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of ATI-450, when used in addition to standard of care therapy.

The primary endpoint is the proportion of subjects who are free from respiratory failure by day 14.

One important feature of ATI-450 that sets it apart from most COVID-19 therapies being tested,is that it is available orally. The vast majority of current COVID-19 therapy programs under investigation that are only available intravenously.

Aclaris is funded to 1Q 2022 not including ongoing efforts to find partners for legacy products/programs. The company enjoys strong institutional support (82%), and 4 analysts have a Buy rating with an average $4.5/share on ACRS stock.

https://seekingalpha.com/instablog/50857529-johnsoriaknows/5482741-aclaris-update-8-7-2020-first-patient-dosed-in-phase-2a-trial-of-atiminus-450-in-hospitalized


 

17.08.20 13:00

5817 Postings, 4208 Tage Kleine_prinzAclaris ATI-450 auch gut gegen krebs?

KU researchers pivot from cancer and cystic fibrosis to test new drug for COVID-19 

August 14, 2020

...................

If this trial shows Gan and Polineni that ATI-450 can be effective at stopping the progression of COVID-19 and keeping people from needing mechanical ventilation, the investigators will be discussing next steps with Aclaris regarding the clinical development of this drug as a potential treatment for inpatients with COVID-19.

The researchers also plan to use what they learn from the trial to inform their other, separate research projects on cancer and CF

.........

http://www.kumc.edu/news-listing-page/gan-polineni.html

 

17.08.20 15:23

5817 Postings, 4208 Tage Kleine_prinzEine Interessante aussage..

KU Medical Center announces drug trial to help fight COVID-19

Info WyandottePosted on Aug 14, 2020Categories COVID-19, Health, Kansas City Kansas, News, Wyandotte CountyTags COVID-19

Dr. Gan had wanted to study the new investigational drug, ATI-450, developed by Aclaris Therapeutics, Inc., that he had wanted to study for its potential to slow metastasis in cancer. Now, he and Dr. Polineni are studying whether it can be used, in conjunction with standard-of-care therapy, to halt respiratory failure in patients hospitalized with COVID-19. If successful, this drug could potentially keep those patients from needing mechanical ventilation.

http://wyandottedaily.com/ku-medical-center-announces-drug-trial-to-help-fight-covid-19/

 

17.09.20 20:43

19767 Postings, 3858 Tage Balu4uÜber 3 Dollar wäre schon mal cool

06.10.20 09:23

19767 Postings, 3858 Tage Balu4uEndlich mal über 3 Dollar

06.10.20 09:44

614 Postings, 1966 Tage oli25Sehr schöne Performance

in letzter Zeit.
Nach 50%- jetzt 70%+ in meinem Depot.
Aber bis wohin kanns gehen?
Bin gerade etwas ratlos, was ich tun soll.
Mitnehmen oder Laufenlassen?
Newsflow war ja top in letzter Zeit und die Pipeline bietet einiges an Potential.
Chart sieht jetzt auch top aus.
Andererseits besteht nach dem Anstieg natürlich auch jederzeit die Gefahr einer KE.
HMMM, echt schwierig im Moment.
Aber ich freue mich natürlich über den Anstieg. :)  

06.10.20 16:40

6265 Postings, 1235 Tage VassagoACRS 3.39$ (neues 52 WH)

Nennenswerte News sehe ich keine.  

08.10.20 16:00
1

614 Postings, 1966 Tage oli25Gewinne mitgenommen

Habe heute meine Gewinne realisiert und bin raus.
Vlt. zu früh. Mal schauen.
Allen Investierten noch viel Glück.
Vlt. gibts ja noch die Option tiefer wieder reinzugehen.
Bleibt definitiv auf Watch.  

08.10.20 16:19

6265 Postings, 1235 Tage VassagoACRS 4.01$

Alles richtig gemacht. Hätte hier auch alle Gewinnen mitgekommen, wenn ich hier investiert gewesen wäre.  

08.10.20 16:28

614 Postings, 1966 Tage oli25Danke Vassago

auch für Deine hervorragende Arbeit hier bei Ariva.
Schade, dass Du nicht mit dabei warst.  

09.10.20 17:02

19767 Postings, 3858 Tage Balu4uVassago....

hätte, würde...!! Ich find's übrigens krass dass du mich grundlos aus einem Thread ausgeschlossen hast. Und hier liegt das Gap Close bei ca. 5 Dollar. Hab noch kein Stück verkauft.  

09.10.20 17:27

19767 Postings, 3858 Tage Balu4uMit Ansage

09.10.20 19:09
1

614 Postings, 1966 Tage oli25Glückwunsch Balu

alles richtig gemacht.
Ich war leider 1 Tag zu früh dran. Bin aber trotzdem zufrieden.
Manchmal sollte man (ich) doch etwas genauer auf die CT schauen.  

09.10.20 21:19

19767 Postings, 3858 Tage Balu4uDanke...

hat mal mit dem Timing geklappt :-)  

Seite: 1 | 2 | 3 | 4 | 5 | 6 | 6   
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
SAP SE716460
BioNTechA2PSR2
Apple Inc.865985
Amazon906866
BYD Co. Ltd.A0M4W9
NEL ASAA0B733
BayerBAY001
TeslaA1CX3T
Allianz840400
Daimler AG710000
BASFBASF11
AlibabaA117ME
NIOA2N4PB
Lufthansa AG823212
JinkoSolar Holdings Co Ltd Sponsored Amercian Deposit Receipt Repr 2 ShsA0Q87R